Compromiso oral en Esclerosis Sistémica

Marina Scolnik

doi:10.47196/rar.v27i4.573

Marina Scolnik Hospital Italiano de Buenos Aires, ciudad Autónoma de Buenos Aires, Argentina

DOI: https://doi.org/10.47196/rar.v27i4.573

Palabras clave: editorial, reumatología

Resumen

El tracto gastrointestinal (GI) está afectado en hasta el 90% de los pacientes con Esclerosis Sistémica (ES). Los síntomas son variados de acuerdo al sitio y grado de compromiso. Disfagia, reflujo, náuseas, vómitos, dolor abdominal, diarrea, constipación, incontinencia fecal y pérdida de peso son los síntomas más comúnmente reportados. El compromiso GI afecta severamente la calidad de vida y es una de las mayores causas de morbimortalidad de la enfermedad.

Biografía del autor/a

Marina Scolnik, Hospital Italiano de Buenos Aires, ciudad Autónoma de Buenos Aires, Argentina

Médica de planta, sección Reumatología

Citas

I. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-205.

II. Clements PJ, Becvar R, Drosos AA, Ghattas L, Gabrielli A. Assessment of gastrointestinal involvement. Clin Exp Rheumatol. 2003;21(3 Suppl 29):S15-8.

III. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology. 2009;48(Supplement 3):iii36-iii39.

IV. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940-944.

V. Scolnik M, Lancioni E, Saucedo C, et al. Systemic sclerosis in Argentina: evaluation of a large cohort from a single centre and comparison with other international series. Clin Exp Rheumatol. 32(6 Suppl 86):S-94-7.

VI. V itali C, Borghi E, Napoletano A, et al. Oropharyngolaryngeal Disorders in Scleroderma: Development and Validation of the SLS Scale. Dysphagia. 2010;25(2):127-138.

VII. Scardina GA, Mazzullo M, Messina P. [Early diagnosis of progressive systemic sclerosis: the role of oro-facial phenomena]. Minerva Stomatol. 51(7-8):311-317.

VIII. Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal Manifestations of Systemic Sclerosis. Dig Dis Sci. 2008;53(5):1163-1174.

IX. C larke, John O; Hirano I. Scleroderma : From Pathogenesis to Comprehensive Management. First Edit. (Varga, John; Denton, Christopher P; Wigley FM, ed.). Springer; 2012.

X. Ramos-Casals M, Brito-Zerón P, Font J. The Overlap of Sjögren’s Syndrome with Other Systemic Autoimmune Diseases. Semin Arthritis Rheum. 2007;36(4):246-255.

XI. Avouac J, Sordet C, Depinay C, et al. Systemic sclerosis– associated Sjögren’s syndrome and relationship to the limited cutaneous subtype: Results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum. 2006;54(7):2243-2249.

XII. Nakamura T, Higashi S, Tomoda K, Tsukano M, Sugi K. Primary biliary cirrhosis (PBC)–CREST overlap syndrome with coexistence of Sjögren’s syndrome and thyroid dysfunction. Clin Rheumatol. 2007;26(4):596-600.

XIII. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-558.